Abstract
Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.
| Original language | English |
|---|---|
| Pages (from-to) | 445-459 |
| Number of pages | 15 |
| Journal | European Journal of Heart Failure |
| Volume | 20 |
| Issue number | 3 |
| Early online date | 15 Jan 2018 |
| DOIs | |
| Publication status | Published - Mar 2018 |
Fingerprint
Keywords
- Journal Article
- Review
Cite this
The innate immune system in chronic cardiomyopathy : a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. / Frantz, Stefan; Falcao-Pires, Ines; Balligand, Jean-Luc; Bauersachs, Johann; Brutsaert, Dirk; Ciccarelli, Michele; Dawson, Dana; de Windt, Leon J; Giacca, Mauro; Hamdani, Nazha; Hilfiker-Kleiner, Denise; Hirsch, Emilio; Leite-Moreira, Adelino; Mayr, Manuel; Thum, Thomas; Tocchetti, Carlo G; van der Velden, Jolanda; Varricchi, Gilda; Heymans, Stephane.
In: European Journal of Heart Failure, Vol. 20, No. 3, 03.2018, p. 445-459.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The innate immune system in chronic cardiomyopathy
T2 - a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC
AU - Frantz, Stefan
AU - Falcao-Pires, Ines
AU - Balligand, Jean-Luc
AU - Bauersachs, Johann
AU - Brutsaert, Dirk
AU - Ciccarelli, Michele
AU - Dawson, Dana
AU - de Windt, Leon J
AU - Giacca, Mauro
AU - Hamdani, Nazha
AU - Hilfiker-Kleiner, Denise
AU - Hirsch, Emilio
AU - Leite-Moreira, Adelino
AU - Mayr, Manuel
AU - Thum, Thomas
AU - Tocchetti, Carlo G
AU - van der Velden, Jolanda
AU - Varricchi, Gilda
AU - Heymans, Stephane
N1 - Funded by Regione Campania CISI-Lab European Union Commission's Seventh Framework . Grant Number: 305507, 602904 FP7-Health-2013-Innovations-1. Grant Number: 602156 FWO Flanders, Belgium. Grant Number: FWO G080014 N European Union Horizon2020. Grant Number: UE LSHM-CT-05-018833, FNRS PDR T.0144.13 Bundesministerium für Bildung und Forschung. Grant Number: BMBF01 EO1004 Deutsche Forschungsgemeinschaft. Grant Number: SFB688 TP A10
PY - 2018/3
Y1 - 2018/3
N2 - Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.
AB - Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.
KW - Journal Article
KW - Review
U2 - 10.1002/ejhf.1138
DO - 10.1002/ejhf.1138
M3 - Review article
C2 - 29333691
VL - 20
SP - 445
EP - 459
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 3
ER -